Immune and viral therapies for malignant primary brain tumors (Q39168899)

9 September 2017

title

Immune and viral therapies for malignant primary brain tumors (English)

1 reference

9 September 2017

Andrew M Gardeck

1

1 reference

9 September 2017

Jordan Sheehan

series ordinal

2

1 reference

9 September 2017

Walter C Low

series ordinal

3

1 reference

9 September 2017

language of work or name

English

0 references

publication date

5 March 2017

1 reference

Expert Opinion on Biological Therapy

9 September 2017

published in

1 reference

9 September 2017

volume

17

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

457-474

1 reference

Malignant gliomas in adults

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A simplified approach for the molecular classification of glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

DNA methylation in glioblastoma: impact on gene expression and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Immune surveillance: a balance between protumor and antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

EGFRvIII-targeted vaccination therapy of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Immunology and immunotherapy in neurosurgical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Dendritic cell vaccines for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Adoptive cell therapies for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Therapeutic Efficacy of Adoptive Cell Transfer on Survival of Patients with Glioblastoma Multiforme: Case Reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Reassessing target antigens for adoptive T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Sleeping beauty system to redirect T-cell specificity for human applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Regression of experimental medulloblastoma following transfer of HER2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Prospects of immune checkpoint modulators in the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Gene therapy for cancer treatment: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Gene therapy: can neural stem cells deliver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Bystander effect in glioma suicide gene therapy using bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Bystander effect in suicide gene therapy using immortalized neural stem cells transduced with herpes simplex virus thymidine kinase gene on medulloblastoma regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Interleukin-12-based immunotherapy against rat 9L glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

NK cells recognize and kill human glioblastoma cells with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Oncolytic poliovirus against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Poliovirus receptor CD155-targeted oncolysis of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Replicative adenoviruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Viruses, gene therapy and stem cells for the treatment of human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Oncolytic (replication-competent) adenoviruses as anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Complement resistance of tumor cells: basal and induced mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

21 January 2018

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Replicative retroviral vectors for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Exploiting the mutanome for tumor vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Unique molecular landscapes in cancer: implications for individualized, curated drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

The cancer cell map initiative: defining the hallmark networks of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1296132

10.1080/14712598.2017.1296132

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference